Literature DB >> 22451924

Tpl2 ablation promotes intestinal inflammation and tumorigenesis in Apcmin mice by inhibiting IL-10 secretion and regulatory T-cell generation.

Oksana B Serebrennikova1, Christos Tsatsanis, Changchuin Mao, Elias Gounaris, Wenying Ren, Linda D Siracusa, Aristides G Eliopoulos, Khashayarsha Khazaie, Philip N Tsichlis.   

Abstract

To address the role of Tpl2, a MAP3K8 that regulates innate/adaptive immunity and inflammation, in intestinal tumorigenesis, we crossed a Tpl2 KO allele into the Apc(min/+) genetic background. Here, we show that Apc(min/+)/Tpl2(-/-) mice exhibit a fivefold increase in the number of intestinal adenomas. Bone marrow transplantation experiments revealed that the enhancement of polyposis was partially hematopoietic cell-driven. Consistent with this observation, Tpl2 ablation promoted intestinal inflammation. IL-10 levels and regulatory T-cell numbers were lower in the intestines of Tpl2(-/-) mice, independent of Apc and polyp status, suggesting that they were responsible for the initiation of the enhancement of tumorigenesis caused by the ablation of Tpl2. The low IL-10 levels correlated with defects in mTOR activation and Stat3 phosphorylation in Toll-like receptor-stimulated macrophages and with a defect in inducible regulatory T-cell generation and function. Both polyp numbers and inflammation increased progressively with time. The rate of increase of both, however, was more rapid in Apc(min/+)/Tpl2(-/-) mice, suggesting that the positive feedback initiated by inflammatory signals originating in developing polyps is more robust in these mice. This may be because these mice have a higher intestinal polyp burden as a result of the enhancement of tumor initiation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22451924      PMCID: PMC3344997          DOI: 10.1073/pnas.1115098109

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  55 in total

Review 1.  IL-10-producing and naturally occurring CD4+ Tregs: limiting collateral damage.

Authors:  Anne O'Garra; Pedro L Vieira; Paulo Vieira; Anne E Goldfeld
Journal:  J Clin Invest       Date:  2004-11       Impact factor: 14.808

2.  Involvement of the Tpl-2/cot oncogene in MMTV tumorigenesis.

Authors:  K M Erny; J Peli; J F Lambert; V Muller; H Diggelmann
Journal:  Oncogene       Date:  1996-11-07       Impact factor: 9.867

3.  Tpl-2 induces IL-2 expression in T-cell lines by triggering multiple signaling pathways that activate NFAT and NF-kappaB.

Authors:  C Tsatsanis; C Patriotis; P N Tsichlis
Journal:  Oncogene       Date:  1998-11-19       Impact factor: 9.867

4.  COX-2 inhibitors for colorectal cancer.

Authors:  D J Elder; C Paraskeva
Journal:  Nat Med       Date:  1998-04       Impact factor: 53.440

5.  Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses.

Authors:  D J Berg; N Davidson; R Kühn; W Müller; S Menon; G Holland; L Thompson-Snipes; M W Leach; D Rennick
Journal:  J Clin Invest       Date:  1996-08-15       Impact factor: 14.808

6.  Tumor progression locus 2 mediates signal-induced increases in cytoplasmic calcium and cell migration.

Authors:  Maria Hatziapostolou; Georgios Koukos; Christos Polytarchou; Filippos Kottakis; Oksana Serebrennikova; Athan Kuliopulos; Philip N Tsichlis
Journal:  Sci Signal       Date:  2011-08-23       Impact factor: 8.192

7.  Tpl-2 is an oncogenic kinase that is activated by carboxy-terminal truncation.

Authors:  J D Ceci; C P Patriotis; C Tsatsanis; A M Makris; R Kovatch; D A Swing; N A Jenkins; P N Tsichlis; N G Copeland
Journal:  Genes Dev       Date:  1997-03-15       Impact factor: 11.361

8.  Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils.

Authors:  K Takeda; B E Clausen; T Kaisho; T Tsujimura; N Terada; I Förster; S Akira
Journal:  Immunity       Date:  1999-01       Impact factor: 31.745

9.  Tumor progression locus 2 (Tpl-2) encodes a protein kinase involved in the progression of rodent T-cell lymphomas and in T-cell activation.

Authors:  C Patriotis; A Makris; S E Bear; P N Tsichlis
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-15       Impact factor: 11.205

10.  T helper cell 1-type CD4+ T cells, but not B cells, mediate colitis in interleukin 10-deficient mice.

Authors:  N J Davidson; M W Leach; M M Fort; L Thompson-Snipes; R Kühn; W Müller; D J Berg; D M Rennick
Journal:  J Exp Med       Date:  1996-07-01       Impact factor: 14.307

View more
  28 in total

1.  Tpl2 inhibitors thwart endothelial cell function in angiogenesis and peritoneal dissemination.

Authors:  Wen-Jane Lee; Keng-Hsin Lan; Chiang-Ting Chou; Yu-Chiao Yi; Wei-Chih Chen; Hung-Chuan Pan; Yen-Chun Peng; Keh-Bin Wang; Yi-Ching Chen; Te-Hsin Chao; Hsing-Ru Tien; Wayne Huey Herng Sheu; Meei-Ling Sheu
Journal:  Neoplasia       Date:  2013-09       Impact factor: 5.715

2.  The combination of TPL2 knockdown and TNFα causes synthetic lethality via caspase-8 activation in human carcinoma cell lines.

Authors:  Oksana B Serebrennikova; Maria D Paraskevopoulou; Elia Aguado-Fraile; Vasiliki Taraslia; Wenying Ren; Geeta Thapa; Jatin Roper; Keyong Du; Carlo M Croce; Philip N Tsichlis
Journal:  Proc Natl Acad Sci U S A       Date:  2019-06-25       Impact factor: 11.205

Review 3.  Macrophages in multiple myeloma: emerging concepts and therapeutic implications.

Authors:  Fotis Asimakopoulos; Jaehyup Kim; Ryan A Denu; Chelsea Hope; Jeffrey L Jensen; Samuel J Ollar; Ellen Hebron; Claire Flanagan; Natalie Callander; Peiman Hematti
Journal:  Leuk Lymphoma       Date:  2013-04-11

4.  Intestinal myofibroblast-specific Tpl2-Cox-2-PGE2 pathway links innate sensing to epithelial homeostasis.

Authors:  Manolis Roulis; Christoforos Nikolaou; Elena Kotsaki; Eleanna Kaffe; Niki Karagianni; Vasiliki Koliaraki; Klelia Salpea; Jiannis Ragoussis; Vassilis Aidinis; Eva Martini; Christoph Becker; Harvey R Herschman; Stefania Vetrano; Silvio Danese; George Kollias
Journal:  Proc Natl Acad Sci U S A       Date:  2014-10-14       Impact factor: 11.205

5.  PRMT5 dimethylates R30 of the p65 subunit to activate NF-κB.

Authors:  Han Wei; Benlian Wang; Masaru Miyagi; Yun She; Banu Gopalan; De-Bin Huang; Gourisankar Ghosh; George R Stark; Tao Lu
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-31       Impact factor: 11.205

6.  MAP3K8 kinase regulates myeloma growth by cell-autonomous and non-autonomous mechanisms involving myeloma-associated monocytes/macrophages.

Authors:  Ellen Hebron; Chelsea Hope; Jaehyup Kim; Jeffrey L Jensen; Claire Flanagan; Neehar Bhatia; Ioanna Maroulakou; Constantine Mitsiades; Shigeki Miyamoto; Natalie Callander; Peiman Hematti; Fotis Asimakopoulos
Journal:  Br J Haematol       Date:  2012-12-18       Impact factor: 6.998

7.  TPL2 kinase is a suppressor of lung carcinogenesis.

Authors:  Katerina Gkirtzimanaki; Kalliopi K Gkouskou; Urszula Oleksiewicz; Georgios Nikolaidis; Dimitra Vyrla; Michalis Liontos; Vassiliki Pelekanou; Dimitris C Kanellis; Kostantinos Evangelou; Efstathios N Stathopoulos; John K Field; Philip N Tsichlis; Vassilis Gorgoulis; Triantafillos Liloglou; Aristides G Eliopoulos
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-26       Impact factor: 11.205

8.  Tpl2 regulates intestinal myofibroblast HGF release to suppress colitis-associated tumorigenesis.

Authors:  Vasiliki Koliaraki; Manolis Roulis; George Kollias
Journal:  J Clin Invest       Date:  2012-10-15       Impact factor: 14.808

9.  Intestinal inhibition of Atg7 prevents tumour initiation through a microbiome-influenced immune response and suppresses tumour growth.

Authors:  Jonathan Lévy; Wulfran Cacheux; Medhi Ait Bara; Antoine L'Hermitte; Patricia Lepage; Marie Fraudeau; Coralie Trentesaux; Julie Lemarchand; Aurélie Durand; Anne-Marie Crain; Carmen Marchiol; Gilles Renault; Florent Dumont; Franck Letourneur; Myriam Delacre; Alain Schmitt; Benoit Terris; Christine Perret; Mathias Chamaillard; Jean-Pierre Couty; Béatrice Romagnolo
Journal:  Nat Cell Biol       Date:  2015-07-27       Impact factor: 28.824

10.  TPL2 kinase regulates the inflammatory milieu of the myeloma niche.

Authors:  Chelsea Hope; Samuel J Ollar; Erika Heninger; Ellen Hebron; Jeffrey L Jensen; Jaehyup Kim; Ioanna Maroulakou; Shigeki Miyamoto; Catherine Leith; David T Yang; Natalie Callander; Peiman Hematti; Marta Chesi; P Leif Bergsagel; Fotis Asimakopoulos
Journal:  Blood       Date:  2014-04-10       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.